Search Result
Results for "
Treg
" in MedChemExpress (MCE) Product Catalog:
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P990042
-
|
ONC-392; BNT 316
|
CTLA-4
|
Cancer
|
|
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .
|
-
-
- HY-P1453A
-
|
|
STAT
|
Cancer
|
|
CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
|
-
-
- HY-B0172A
-
|
3β-Hydroxy-5α-cholanic acid
|
Others
|
Inflammation/Immunology
|
|
Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a T cell regulator. Isoallolithocholic acid enhances regulatory T cells (Tregs) differentiation .
|
-
-
- HY-119217
-
AZ084
2 Publications Verification
|
CCR
|
Inflammation/Immunology
Endocrinology
|
|
AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma . AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer .
|
-
-
- HY-144200
-
|
|
CCR
|
Neurological Disease
Cancer
|
|
CCR8 antagonist 2 is a potent antagonist of CCR8. CCR8 (C-C Motif Chemokine Receptor 8) is predominantly expressed on Treg cells and Th2 cells, but not on Th1 cells. CCR8 antagonist 2 inhibits CCR8 activity, which may be used in the research of diseases mediated by CCR8, such as cancer, and/or neuropathic pain (extracted from patent WO2022000443A1, compound 220) .
|
-
-
- HY-P2520
-
-
-
- HY-P1453
-
|
|
STAT
|
Cancer
|
|
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
|
-
-
- HY-162943
-
|
|
PROTACs
|
Cancer
|
|
P60-L3-VHL is a PROTAC-class Foxp3 degrader. P60-L3-VHL reduced cell differentiation and Foxp3 expression in activated Treg cells in vitro and had anti-tumor activity (Blue: E3 ligase ligand (HY-162945); Pink: target protein ligand (HY-162946); Black: linker (HY-162947)) .
|
-
-
- HY-125836
-
|
|
CCR
|
Endocrinology
Cancer
|
|
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues.
CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca 2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .
|
-
-
- HY-104026B
-
-
-
- HY-B0172AS
-
-
-
- HY-137206
-
|
|
Ligands for E3 Ligase
Molecular Glues
|
Cancer
|
|
ALV2 is a potent and selective Helios degrader. ALV2 binds CRBN, with an IC50 of 0.57 μM. Helios is the zinc-finger transcription factor that can maintain a stable Treg cell phenotype in the inflammatory tumor microenvironment .
|
-
-
- HY-104026CS
-
-
-
- HY-162275
-
|
|
Others
|
Cancer
|
|
JMJD1C-IN-1 (compound 193D7) is an inhibitor of JMJD1C with oral activity. JMJD1C-IN-1 targets tumor Treg cells without affecting systemic immune homeostasis .
|
-
-
- HY-104026BS
-
-
-
- HY-P4790
-
|
|
PI3K
Akt
|
Metabolic Disease
|
|
Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation .
|
-
-
- HY-125783
-
-
-
- HY-120785A
-
|
|
ROR
|
Inflammation/Immunology
|
|
SR1555 hydrochloride is the hydrochloride salt form of SR1555 (HY-120785). SR1555 hydrochloride is an inverse agonist for retinoic acid receptor-related orphan nuclear receptor γ (RORγ) with an IC50 of 1 μM. SR1555 hydrochloride inhibits the development and function of pro-inflammatory TH17 cell, increases the frequency of anti-inflammatory T regulatory (Treg) cells. SR1555 hydrochloride can be used for research about autoimmune diseases .
|
-
-
- HY-148494
-
|
FLX475
|
CCR
|
Inflammation/Immunology
Cancer
|
Tivumecirnon (FLX475) is an orally bioactive, selective CCR4 antagonist. Tivumecirnon can block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment, leading to enhanced antitumor activity. Tivumecirnon has antitumor activity on EBV+ NK/T cell lymphoma and non-small cell lung cancer (NSCLC) combined with Pembrolizumab (HY-P9902). Tivumecirnon is promising for research of broad range of tumor types .
|
-
-
- HY-155505
-
|
|
Aryl Hydrocarbon Receptor
|
Inflammation/Immunology
|
|
AHR agonist 4 (compound 24e) is an agonist of Aryl hydrocarbon receptor (AHR), assocaited with the immune balance of Th17/22 and Treg cells. AHR agonist 4 serves as a lead compound for anti-psoriasis drug, alleviates imiquimod (IMQ)-induced psoriasis-like skin lesion . AHR agonist 4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-126675A
-
|
|
CDK
STAT
|
Inflammation/Immunology
|
|
AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene .
|
-
-
- HY-126675
-
|
|
CDK
STAT
|
Inflammation/Immunology
|
|
AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene .
|
-
-
- HY-103637
-
|
VTP-43742
|
ROR
|
Inflammation/Immunology
|
|
Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research .
|
-
-
- HY-103637A
-
|
VTP-43742 hydrochloride
|
ROR
|
Inflammation/Immunology
|
|
Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research .
|
-
-
- HY-P2294
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
pm26TGF-β1 peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide shows high affinity for the TGF-β1 receptor. pm26TGF-β1 peptide displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction .
|
-
-
- HY-P2294A
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
pm26TGF-β1 TFA peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide TFA shows high affinity for the TGF-β1 receptor. pm26TGF-β1 peptide TFA displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction .
|
-
-
- HY-W016773
-
|
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
|
1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatory T cells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism .
|
-
-
- HY-162415
-
|
|
c-Fms
Apoptosis
|
Cancer
|
|
CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 + T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 + T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1453A
-
|
|
STAT
|
Cancer
|
|
CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
|
-
- HY-P2294A
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
pm26TGF-β1 TFA peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide TFA shows high affinity for the TGF-β1 receptor. pm26TGF-β1 peptide TFA displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction .
|
-
- HY-P2520
-
-
- HY-P1453
-
|
|
STAT
|
Cancer
|
|
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
|
-
- HY-P4790
-
|
|
PI3K
Akt
|
Metabolic Disease
|
|
Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation .
|
-
- HY-P2294
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
pm26TGF-β1 peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide shows high affinity for the TGF-β1 receptor. pm26TGF-β1 peptide displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99327
-
|
BT-061
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
|
-
- HY-P990042
-
|
ONC-392; BNT 316
|
CTLA-4
|
Cancer
|
|
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .
|
-
- HY-P990031
-
|
M-6223
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0172AS
-
|
|
|
Isoallolithocholic acid-d2 is the deuterium labeled Isoallolithocholic acid (HY-B0172A). Isoallolithocholic acid is a T cell regulator and enhances regulatory T cells (Tregs) differentiation[1][2].
|
-
-
- HY-104026CS
-
|
|
|
L-Kynurenine- 13C10 (sulfate hemihydrate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate hemihydrate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .
|
-
-
- HY-104026BS
-
|
|
|
L-Kynurenine-13C10 (sulfate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-155505
-
|
|
|
Alkynes
|
|
AHR agonist 4 (compound 24e) is an agonist of Aryl hydrocarbon receptor (AHR), assocaited with the immune balance of Th17/22 and Treg cells. AHR agonist 4 serves as a lead compound for anti-psoriasis drug, alleviates imiquimod (IMQ)-induced psoriasis-like skin lesion . AHR agonist 4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-125783
-
|
|
|
Phospholipids
|
|
1-Palmitoyl-sn-glycero-3-phosphocholine is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .
|
-
- HY-159692
-
|
IONIS-1063734
|
|
Antisense Oligonucleotides
|
|
AZD8701 (IONIS-1063734) is an antisense oligonucleotide targeting FOXP3 in regulatory T cells (Tregs). AZD8701 can relieve immunosuppression in cancer .
|
-
- HY-159692A
-
|
IONIS-1063734 sodium
|
|
Antisense Oligonucleotides
|
|
AZD8701 (IONIS-1063734) sodium is an antisense oligonucleotide targeting FOXP3 in regulatory T cells (Tregs). AZD8701 sodium can relieve immunosuppression in cancer .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
